Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting

Research output: Contribution to journalReview article

Abstract

Purpose of review: A burst of recent activity has surrounded the study of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors for the treatment of metastatic breast cancer. The success of these drugs in the metastatic setting has pushed the evaluation of these agents in early-stage disease. The use of CDK 4/6 inhibitors as neoadjuvant and adjuvant therapy is a hot topic and several studies are underway. Recent findings: Ongoing studies are exploring the addition of CDK 4/6 inhibitors to endocrine therapy in early breast cancer. Summary: Identification of the optimal treatment combinations is the goal of current research. Finding biomarkers for patients' selection will be the goal of future research.

Original languageEnglish
Pages (from-to)428-433
Number of pages6
JournalCurrent Opinion in Oncology
Volume29
Issue number6
DOIs
Publication statusPublished - Nov 1 2017

Keywords

  • adjuvant
  • breast cancer
  • CDK 4/6 inhibitors
  • neoadjuvant

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting'. Together they form a unique fingerprint.

  • Cite this